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Background: Clove oil of Eugenia caryophyllata (Myrtaceae) is a light yellowish fluid obtained from dried
flower buds. Clove oil is used traditionally to relieve toothache.
Aim: The aim of the present work was to study the anti-inflammatory, antinociceptive and antipyretic
potential of clove oil in mice.
Methods: Analgesic activity was examined using acetic-acid-induced abdominal constrictions and the hot
plate test. Carrageenan-induced paw edema and brewer’s-yeast-induced pyrexia were used to investigate the
anti-inflammatory activity and the antipyretic effects, respectively. The oil was administered intraperitoneally
(i.p.) at a dose of 33 mg/kg body weight and the effects were compared with reference drugs.
Results: In the antinociceptive test, mice treated with clove oil exhibited significantly decreased acetic-acid-
induced writhing movements by a maximum of 87.7% (pB0.01) compared with a decrease of 77.7% (pB0.01)
in response to aspirin injection (100 mg/kg, intraperitoneal, i.p.). Similarly, in the hot plate test, clove oil
significantly increased the reaction latency to pain after 60 min by 82.3% (pB0.05) compared with morphine
value of 91.7% (pB0.01). In addition, clove oil and indomethacin produced anti-inflammatory effects, as
demonstrated by respectively 50.6% (pB0.05) and 70.4% (pB0.01) inhibition of mouse paw edema induced
by carrageenan. Furthermore, clove oil significantly attenuated the hyperthermia induced by yeast at DT-max
by 2.78C (pB0.001), and time of peak effects was 30180 min compared with a paracetamol value DT-max of
3.28C (pB0.001). The estimated i.p. LD50 of clove oil was 161.9 mg/kg. Phytochemical screening of the oil
showed the presence of eugenol.
Conclusion: The present findings demonstrate the potential pharmacological properties of clove oil and
provide further a support for its reported use in folk medicine.
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O
ver the centuries, plants have been used for their
medicinal values. However, many plants have yet
to be studied and relatively few scientific re-
searches have been carried out. Therefore, assessment of
medicinal plants is of special interest because of rich heri-
tage and the continuous use among large portion of
people.
Clove is an evergreen plant 1020 cm tall found
throughout the hot tropical climates. It was originally
from Asian tropical countries. Clove, Syzygium aro-
maticum L. (Eugenia caryophyllata, syn.), belongs to the
family Myrtaceae. It has a strong phenolic smell and sharp
pungent taste. The dried flower bud is commonly used as a
spice. The oil, steam distilled from clove buds, is a colorless
to light yellowish fluid heavier than water and freely
soluble in alcohol (1).
Humans have consumed clove over a long period of
time. In addition to its flavoring properties, it is known for
its medicinal advantages. In Ayurveda, Chinese medicine
and Western herbalism, clove has been valued as a herbal
remedy. For years, clove has been used as antispasmodic,
carminative and to improve peristalsis (1). The essential
oil of clove is used for dental emergencies, mainly for
symptomatic relief of toothache and inflammation in the
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mouth and throat. In this regard, clove oil has been re-
ported to be used in preparation of certain toothpastes and
mouth washes (1). In the recent past, studies have de-
monstrated that clove is antimutagenic (2), antioxidant,
antithrombotic, antiparasitic and anti-inflammatory (3).
In addition, clove oil is stated to possess antibacterial,
antiviral and antifungal properties (46).
Evidence from numerous studies has shown the several
constituents of clove, mainly eugenol (7090%), tanene
(13%) and fixed oil (10%) (7). Different studies evaluated
the effects of these compounds on physiological para-
meters and their potential health-related significance.
Studies in the arthritic rat model have shown that eugenol
exhibits anti-inflammatory and anti-arthritic activities (8).
Feng and Lipton (9) have demonstrated that eugenol sig-
nificantly reduced fever when given to rabbits made febrile
by the injection of interleukin 1. These findings provide
support for some of the traditionally accepted medicinal
uses of clove oil. However, the ethno-pharmacological
properties of the native oil as it is used traditionally have
not been investigated. Therefore, to provide more informa-
tion, the present study aimed to study the oil available
in public markets and pharmacy shops for dentistry pur-
poses for possible antinociceptive, antipyretic and anti-
inflammatory potential in mice.
Materials and methods
Animals
Inbred male Albino mice aged 23 months weighting
1735 g and reared in our animal house were used in all
experiments. Mice were maintained on standard husban-
dry condition of humidity and temperature (25928C) with
a 12-h light/dark cycle, and had free access to animal
pellets and water. Food was withheld overnight before the
experiments while water was still provided ad libitum. All
experiments were run during the day time. The experi-
mental protocol, dated August 25, 2002, was reviewed and
approved by the Ethics Committee for Research Programs
(Faculty of Pharmacy, Tripoli University, Tripoli, Libya)
under Ref. No. Pharm/23/09/2002/2003. Laboratory
animal care and use was in strict accordance with the
guidelines of animal welfare. The study was done on 110 mice
(1824 mice per experiment), in three groups of 68 mice
for each experiment.
Drugs and chemicals
The following drugs were used: aspirin, indomethacin,
Lambda-carrageenan Type IV (Sigma Chemical Co., St.
Louis, USA), paracetamol (Bristol-Myers Squibb, Italy)
and morphine (Lavoisier, France). The doses were selected
according to previous studies (10, 11). All other chemicals
were of analytical grade. Clove oil, (0.03% w/v, Al-Asi for
antiseptic Co., Halib, Syria, batch no. 123) was bought
from local market, Tripoli, Libya. The composition of the
clove oil was 100% natural. The dose of clove oil (33 mg/kg
body weight) was based on the literature (8). A bent
blunted 25 g needle connected to a 1-ml syringe was used
for i.p. administration.
Phytochemical screening
The oil was screened phytochemically for the presence of
the phenolic substance eugenol. The method of analysis
was a standard technique according to the color test pro-
cedure previously mentioned elsewhere (12, 13). Briefly,
the presence of eugenol, the main phenolic constituent of
clove oil, was tested by dissolving two drops of the oil in
1 ml 70% ethanol followed by addition of a few drops of
1% alcoholic ferric chloride.
Anti-inflammatory activity
The anti-inflammatory activity of clove oil was investi-
gated by the use of carrageenan-induced paw edema test as
described previously in mice (14). Briefly, in three groups
of six mice each, 0.02 ml of a freshly prepared suspension
of the phlogistic agent carrageenan in saline (10 mg/ml)
was injected sub-plantar into the right hind paw of each
mouse. Thirty minutes before carrageenan injection mice
were treated i.p. by clove oil, negative and positive control
mice received normal saline and indomethacin, respec-
tively. Paw thickness was measured before and 3 h after car-
rageenan injection, using a micrometer (Mitutoyo, Japan).
The increase in paw thickness was taken as an indicator of
the degree of acute inflammation and edema. The percen-
tage inhibition of the inflammatory response was deter-
mined for every mouse in comparison to saline-treated
animals and computed using the following formula (14):
Percent inhibition ¼ 100 ½ðEPT=CPTÞ  100
where EPT represents experimental paw thickness and
CPT represents control paw thickness.
Analgesic activities
The writhing acetic acid test was used to evaluate the
possible peripheral effects of the oil as an analgesic and
was performed as previously described (14). Briefly, clove
oil, aspirin, or an equivalent volume of saline (negative
control) was given i.p. before the injection of 10 ml/kg of
0.6% v/v acetic acid. Each mouse was then placed in an
observation box for 20 min. The number of constrictions
of the abdominal muscles together with stretching of
the hind limbs, an indication of writhing response, was
counted. Antinociceptive activity was expressed as the
number of abdominal constrictions in mice pre-treated
with clove oil or aspirin relative to control animals. The
formula used for the calculation of percentage of writhing
inhibition was as follows (14):
Percent inhibition ¼ ½control mean treated mean
 100=control mean:
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Thermally induced pain in mice
The Eddy’s hot plate test was used for assessment of
possible centrally mediated analgesic effects of clove oil.
This method was applied to assess response latencies as
described (14). For two consecutive days before the
experiments, mice were placed gently on a plate (Model-
DS37) maintained at 25918C for 10 min each day. On the
third day, each mouse was placed quietly on a hot plate at
55918C for a maximum of 25 sec. Licking of forepaws,
shaking or jumping off the plate was recorded and used as
a nociceptive response baseline reading. Clove oil was
given i.p., whereas the central analgesic drug, morphine,
used as a positive control, was injected subcutaneously
(s.c.). Negative control mice received normal saline i.p.
After 30 min, the latency time in each mouse was recorded
to determine the analgesic response. Full analgesia was
considered as a latency of 25 sec. The mean latency of
nociceptive responses for each treatment group was
calculated. The percentage of analgesia was calculated
using the following formula (14):
Percent analgesia ¼ ðr fÞ  100=r
where s represents reaction time after treatment and
z represents baseline recording.
Antipyretic test
The antipyretic test was done in the model of pyrexia
induced by brewer’s yeast (15). Temperature was mea-
sured with a lubricated digital thermometer (SK-1250
MC, Sato Keiryoki Mfg.) inserted approximately 2 cm
into the rectum for 60 sec. Hyperthermia was induced in
mice 18 h before treatment by s.c. injection below the
neck of 1 ml/100 g body weight of a 20% w/v aqueous
suspension of brewer’s yeast. The first measurement was
made immediately before the yeast injection. After 17 h,
rectal temperature of each mouse was recorded. Each
mouse exhibiting an increased rectal temperature of at
least 0.78C was selected for the investigation. This rectal
temperature was indicated as baseline reading. Clove oil,
paracetamol and saline were administered i.p. The
response in each mouse was taken as the difference in
rectal temperature after 0.5, 1, 2 and 3 h from the baseline
reading. Percentage inhibition of fever (% if) was
calculated according to the following formula:
Percent if¼ ðPYT PDTÞ  100=PYT
where, PYT represents post-yeast temperature and PDT
represents post-drug treatment.
Acute toxicity study (LD50)
The protocol used for acute toxicity study has been
described (16). Briefly, in all groups, 5% dextrose, ad
libitum, was used to replace the withheld food and to avoid
stress and starvation of mice during the experiment. LD50
was defined as 50% deaths within 96 h after clove oil
administration. Mice were divided into five groups (n4
each). Four groups of four mice each were given the oil i.p.
at doses 50, 90, 162 and 292 mg/kg body weight, res-
pectively. Group 5, used as the control, received water at
10 ml/kg. After injection, mice were observed continuously
for the first 3 h for any toxic manifestation or behavioral
changes. Thereafter, deaths were monitored every 212 h
for up to 4 days. The LD50 was calculated using the
following formula (17):
Log m ¼ log Da þ d: ðf þ 1Þ
where, log m represents the log of LD50, log Da represents
the log of the smallest of the four doses used, d represents
the logarithm of the constant ratio between dosage levels,
and f represents a constant factor obtained from Weil’s
tables.
Statistical analysis
The data were found to be normally distributed based on
the K-S statistical goodness of fit test. LD50 (Table 2) was
obtained algebraically as described above. The results are
expressed as mean9SEM. The variance between groups
was tested by ANOVA followed by Tukey’s test. For the
anti-inflammatory experiment (Fig. 1), the difference was
calculated on the individual changes recorded between
the paw thickness obtained before and 3 h after carragee-
nan injection. In the study of antinociceptive activities,
comparison was done on the individual pain reactions in
the abdominal constrictions test observed in control and
test animals (Fig. 2), and between the individual reaction
times obtained before and after treatment in the Eddy’s
Fig. 1. Effects of i.p. administration of clove oil and indo-
methacin (10 mg/kg) on mouse paw edema 3 h after injection
of carrageenan. Mean9SEM of eight individual measure-
ments of increase in paw thickness is presented (n8 each
mouse group). aAdministered 30 min before carrageenan
injection. ##pB0.01 vs. pre-carrageenan injection (paired
t-test), *pB0.05, **pB0.01 vs. control mice (ANOVA followed
by Tukey’s test).
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hotplate test (Fig. 3). For the antipyretic test (Table 1),
comparisons were made on the individual differences
calculated between the rectal temperature at each record
and the one obtained 17 h after yeast injection. pB0.05
was considered as significant values against respective
control. GraphPad Prism (GraphPad Software Inc.,




In control mice, carrageenan induced significant swelling
of the mouse paw, which reached a maximum thickness
of 22.3 (SEM93.9) mm in 3 h (86.2% increase compared
with before carrageenan injection, (pB0.01, Fig. 1), and
gradually declined over the next hours (data not shown).
The clove oil injected 30 min before carrageenan led to
considerable inhibition of the induced edema. Clove oil
significantly suppressed the increase in paw thickness by
50.6% (pB0.05) compared with control mice (Fig. 1).
Indomethacin produced a greater edema inhibition (70.4%
suppression, pB0.01) than that of clove oil compared
with control group. The effect of indomethacin was not
significantly different (p0.05) from that of clove oil
within the same period.
Antinociceptive activity
Acetic-acid-induced writhing in mice
In all treatment groups, mice showed no sign of abdominal
constriction before acetic acid injection, among all con-
trols and all clove-oil-treated animals. Twenty minutes
after injection with acetic acid, mice that had received
normal saline showed obvious abdominal constrictions
(94.899.79) as judged by the number of writhing response
related to that before injection. Compared with the control
group, mice treated with clove oil exhibited fewer writhing
responses (12.391.28 writhes). As Fig. 2 shows, clove oil
significantly suppressed the development of acetic-acid-
induced abdominal constrictions and stretching of hind
limbs by 87.7% (pB0.01). The reference drug, aspirin, also
effectively suppressed the number of writhes significantly
by 77.7% (pB0.01) compared with control mice (Fig. 2).
In this nociception model, the analgesic effect of clove oil
was more prominent, and was significantly higher than
that produced by aspirin (12.3 vs. 21.2 writhes, respectively,
pB0.05).
Thermally induced pain in mice
The results of the hot plate test are presented in Fig. 3.
Treatment with clove oil resulted in significant analgesic
activity (pB0.05) compared with control group. The
analgesic effect produced by clove oil was characterized
by a considerable increase in the latency of the reaction to
heat sensation from 1.191.77 sec to 6.291.39 sec (82.3%
analgesia). The reference drug morphine also signifi-
cantly delayed the reaction time by 91.7% (pB0.01)
compared with control mice. The antinociceptive effect
elicited by morphine was significantly stronger than that
produced by clove oil (13.392.53 sec vs. 6.291.39 sec,
respectively, pB0.05; Fig. 3).
Antipyretic activity
The effects of clove oil and paracetamol on yeast-induced
pyrexia in mice are shown in Table 1. The s.c. injection of
Fig. 2. Effect of clove oil on the number of writhing induced
by acetic acid injection in mice. Control mice received normal
saline and positive control group was treated with aspirin (100
mg/kg). Mean9SEM of eight individual readings is presented
(n8 each group). aAdministered 0.5 h before acetic acid
injection (0.6% v/v, 10 ml/kg, i.p.). *pB0.01 vs. control group.
#pB0.05 vs. aspirin-treated mice.
Fig. 3. The effect of clove oil and morphine (5 mg/kg)
against thermally induced pain by the hot-plate method in
mice. Mean9SEM of eight individual readings is presented
(n8 each group). aAdministered 0.5 h before thermal
stimulus at 55918C. *pB0.05, **pB0.01 vs. control mice.
#pB0.05 vs. morphine-treated mice.
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an aqueous suspension of brewer’s yeast significantly
increased the rectal temperature by 0.78C after 17 h of
administration. Control mice displayed an increase in
rectal temperature from 37.490.218C to 39.290.258C
(pB0.001). Mice treated with clove oil and paracetamol
(positive control) exhibited significantly decreased rectal
temperature compared with the control group. Clove oil
showed significant suppression in rectal temperature by
2.78C, from 39.090.178C to 36.390.328C (pB0.001),
and the percentage inhibition of fever was 6.9%. The
antipyretic effect of clove oil started 30 min after
injection of the oil (pB0.01) and the reduction in rectal
temperature was maintained for 3 h (pB0.001). Para-
cetamol also induced a significant reduction in rectal
temperature of 3.28C, from 39.590.128C to 36.239
0.278C, and the percentage inhibition of fever was 6.9%
(pB0.001) for respective group. There was no significant
difference between the antipyretic effect of clove oil and
that produced by paracetamol. Normo-thermic mice did
not show a decrease in rectal temperature after admin-
istration of clove oil (data not shown).
LD50 assessment
Table 2 shows that the median (i.p.) LD50 of clove oil was
161.9 mg/kg with a 95% Cl of 106.9244.9 mg/kg. Mice
treated with up to 50 mg/kg clove oil and observed for 96 h
did not show abnormal symptoms, consistent with no
decrease in food intake (data not shown). Furthermore, no
deaths were observed. These data indicate that the toxicity
of the clove oil is limited. Injection of doses ]90 mg/kg
body weight produced various observable effects, includ-
ing in motor activity and respiration, within 45 min. Mice
showed ataxia, sedation and decreased motor activity,
piloerection, tremor, ptosis and 25% mortality. Also, a
dose-dependent mortality was observed after increasing
the doses: 292 mg/kg clove oil was 100% lethal (Table 2).
Phytochemical test
The color test used in this study showed the formation of
a bluegreen color, signifying the presence of the phenolic
substance, eugenol, in the clove oil.
Discussion
It is well known that several mechanisms are involved in
analgesic activity. The antinociceptive property of clove oil
was examined using different mouse models. i.p. injection
of acetic acid produces algesia by increasing endogenous
substances, including prostaglandins in peritoneal fluids,
such as PGF2a and PGE2, as well as histamine and
serotonin. This model is generally used for assessment
peripheral analgesics (18). The use of the thermal method
is deemed to be selective for opioid-like substances, which
are centrally acting analgesics in different animal models.
It is commonly used particularly for evaluation of cen-
tral pain at the supraspinal and spinal levels, since it
encompasses neurogenic and central mechanisms of noci-
ception (19). Our results showed that clove oil consider-
ably inhibited acetic-acid-induced writhing in mice and
Table 1. The effect of clove oil and paracetamol on brewer’s yeast-induced fever in mice
Group Control Paracetamola Clove oila
Dose (mg/kg)  100 33
Initial body temperature 0 h 37.490.21 37.190.22 37.290.12
Post-yeast temperature 17 h 39.290.25b* 39.590.12b** 39.090.17b**
0.5 h 39.190.20b* 37.490.30c# 37.690.37c#
Rectal % if 4.34 3.96
temperature (C8) 1 h 39.290.22b** 36.790.24c## 37.290.58c#
Post-drug treatment % if 6.40 5.18
2 h 39.090.23b** 36.690.17c## 36.390.32c##
% if 6.03 6.86
3 h 38.990.19b* 36.390.27c## 37.090.29c##
% if 6.88 5.09
Values are expressed as mean9SEM rectal temperature (n6 each group). ANOVA followed by Tukey’s multiple comparison tests.
aAdministered 18 h after yeast injection; bcompared to 0 h (paired t-test); ccompared to control group; % if% inhibition of fever.
*pB0.01, **pB0.001, #pB0.01 and ##pB0.001 vs. control values.
Table 2. LD50 determination in mice
Group n
Dose
(mg/kg body weight) No. of deaths % Mortality
1 4 50 0/4 0
2 4 90 1/4 25
3 4 162 1/4 25
4 4 292 4/4 100
5 4 Control  0
Log mlog Dad. (f1).
Log mlog 50log 1.8 (11)2.209245.
LD50 (i.p.)161.9 mg/kg.
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increased pain latency time (the neurogenic pain) caused
by thermal stimuli. These results indicated that clove oil
possessed analgesic activity. In addition, the present study
showed that clove oil has antipyretic and anti-inflammatory
effects in experimental animals with a reasonable safety
profile. These findings give a rational authentication for
their traditional indications.
Carrageenan-generated paw edema is an established
well-known experimental model for acute inflammation.
This model has significant predictive value for evaluation
of antiedematogenic compounds acting by interfering with
the inflammatory mediators (14). Carrageenan as a phlo-
gistic agent is non-antigenic and is devoid of apparent
systemic activity (20). So far, several investigators have
demonstrated that acute edema inflammation, due to
carrageenan injection, has biphasic upshots. Histamine
and serotonin trigger the first phase (21, 22), while, the
later phase of inflammation in which the edema reaches its
highest degree is elicited mostly by the release of prosta-
glandins (21, 22). It has been shown that prostaglandins
encourage the formation of the inflammatory exudates
during tenderness. This demagogic effect of prostaglandins
is considerably attenuated by the use of non-steroidal anti-
inflammatory drugs (NSAID) (23). Our observation that
clove oil effectively suppressed this acute inflammation
indicated that it has antiedematogenic activity. However,
the mechanisms by which clove oil induced suppression of
edema formation are not known at present. Although it
cannot be excluded that abrogation of one of the two inflam-
matory mediators, histamine and serotonin, is responsible
for the anti-inflammatory activity of clove oil, our obser-
vation that clove oil ameliorated edema formation during
the late phase, 3 h after carrageenan injection, demon-
strates that the effectiveness of clove oil is probably
mediated through its interference with prostaglandins.
The usual classification of the antinociceptive drugs is
based on their mechanism of actions, either on the central
nervous system (CNS) or on the peripheral pathway. In
this study, two different animal models were used with the
goal of identifying potential peripheral or central effects
of clove oil. Acetic-acid-induced abdominal constriction,
as a model of visceral pain, is a highly sensitive method
able to reveal the antinociceptive potential of drugs at
doses that might appear inactive in other pain reliever
patterns. So, this model is commonly used for the
assessment of the peripheral pathway of analgesic drugs.
Previous studies have demonstrated that acetic acid
stimulates the pain nerve endings and induces contrac-
tion of abdominal muscle via the sensitization of the
nociceptive receptor to the peripherally released prosta-
glandins, in particular PGE2a and PGF2a (18). It has
been shown that inhibition of prostaglandins by aspirin
and other related NSAIDs is involved in the protection
against induction of pain (23). Therefore, although the
mechanism of clove oil in this study is not clear, it seems
likely that inhibition of prostaglandins contributes to
its effectiveness in protecting mice from visceral pain.
Thus, this and the observation that clove oil, when given
before carrageenan, appeared to inhibit the late phase of
inflammation, indicates that inhibition of prostaglandins
peripherally is a mechanism by which clove oil induces its
pharmacological effect. This conclusion is further sup-
ported by our findings that clove oil effectively inhibited
yeast-induced fever in a mouse model of hyperpyrexia.
It is well known that NSAIDs usually do not raise the
pain threshold in normal tissues, while narcotic drugs do
(24). Studies have demonstrated that pain generated by a
thermal stimulus is mediated centrally (19, 25). In this
model, the effects of drugs on latency time of jumping
responses or licking of the animal’s front paws represents
the analgesic effect on sensory receptor stimulation.
Therefore, our observation that clove oil prolonged the
reaction time, like morphine, demonstrates that the
analgesic effect of clove oil was in part mediated centrally.
These findings are in agreement with other reports
illustrating that the analgesic effect of clove oil is CNS
dependent (26). Our observation that higher doses of
clove oil had a sedative effect might also explain the
central effect observed in the hot plate test.
The present study shows that clove oil has antipyretic
activity in mice made febrile by the use of dried yeast. A
number of studies have demonstrated that yeast-induced
pyrexia is a pathogenic fever (27, 28). In the hypothalamus,
the production of prostaglandins, due to fever induction,
sets the thermoregulatory center at a higher temperature.
It is well known that NSAIDs decrease body temperature
by inhibiting prostaglandin synthesis within the hypotha-
lamus (29, 30). Therefore, we suggest that the antipyretic
effect of clove oil in our model is mediated by inhibition
of prostaglandin biosynthesis in hypothalamus.
The oil was devoid of signs of toxicity when given to
mice. Though chronic toxicity was not studied here, ab-
sence of acute destructiveness symptoms explains its wide-
spread use in folk medicine. Since the estimated i.p. LD50
of clove oil was 161.90 mg/kg, a five fold higher than the
effective dose, it indicates that the dose required to produce
the therapeutic effects is acceptably lower the toxic dose.
Previous studies have demonstrated that eugenol, the
major constituent of clove oil, has anti-inflammatory
activity in rats, peripheral but not central analgesic effects
in mice (31), and antipyretic activity in rabbits (9). In vitro
experiments also showed that eugenol inhibits COX-2
enzyme in the macrophage cell line RAW264.7 (32). In
addition, eugenol has been reported to inhibit prostaglan-
din synthesis in blood platelets (8). Hence, it seems likely
that the peripheral potential effects of clove oil were
attributed to their eugenol content, while the CNS effects
is indorsed by other active ingredients found in the oil (7).
The present study has a few limitations. First, the use
of the i.p. route of administration may limit extrapolation
Yousef A. Taher et al.
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of our results since clove oil is not commonly used by this
route. The second limitation is that because the experi-
ments were performed a long time ago, new developments
in this field are not taken into consideration. However,
the present study gives clear evidence on some pharma-
cological properties of clove oil.
In summary, our data demonstrate that clove oil has
valuable pharmacological properties in mice. We showed
that pain, fever and acute inflammation, induced experi-
mentally in mice, were considerably ameliorated by the
use of clove oil. The effective dose of clove oil was
sufficiently below the LD50 value. These findings need
further experiments to elucidate the underlying mechan-
isms involved in the pharmacological effects of clove oil.
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